Citations

Mayo Clinic

Clear

4604 citation(s) found for "Na, Brian".

Unsupervised Classification of High-Frequency Oscillations in Human Neocortical Epilepsy and Control Patients
Blanco, Justin A. , Stead, Matt, Krieger, Abba Μ. , Viventi, Jonathan , Marsh, W. Richard , Lee, Kendall H. , Litt, Brian , Worrell, Gregory A.

Journal of Neurophysiology | September 2, 2010 | Volume: 104 | Issue: 5 | Pages: 2900-2912

10.1152/jn.01082.2009 | PMID 20810694 Get It

High-frequency oscillations (HFOs) have been observed in animal and human intracranial recordings during both normal and aberrant brain states. It has been proposed that the relationship between subclasses of these oscillations can be used to identify epileptic brain. Studies of HFOs in epilepsy have been hampered by selection bias arising primarily out of the need to reduce the volume of data so that clinicians can manually review it. In this study, we introduce an algorithm for detecting and classifying these signals automatically and demonstrate the tractability of analyzing a data set of unprecedented size, over 31,000 channel-hours of intracranial electroencephalographic (iEEG) recordings from micro- and macroelectrodes in humans. Using an unsupervised approach that does not presuppose a specific number of clusters in the data, we show direct evidence for the existence of distinct classes of transient oscillations within the 100- to 500-Hz frequency range in a population of nine neocortical epilepsy patients and two controls. The number of classes we find, four (three plus one putative artifact class), is consistent with prior studies that identify “ripple” and “fast ripple” oscillations using human-intensive methods and, additionally, identifies a less examined class of mixed-frequency events.
Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
Maurer, Matthew J. , Link, Brian K. , Ansell, Stephen M. , Micallef, Ivana N. , Kelly, Jennifer L., Macon, William R. , Nowakowski, Grzegorz S. , Inwards, David J. , Johnston, Patrick B. , Allmer, Cristine, Weiner, George J. , Cerhan, James R. , Drake, Matthew T. , Habermann, Thomas M. , Singh, Ravinder J. , Slager, Susan L. , Witzig, Thomas E. , Maurer, Matthew , Cerhan, James R , Link, Brian K , Weiner, George

Journal of Clinical Oncology | August 17, 2010 | Volume: 28 | Issue: 27 | Pages: 4191-4198

10.1200/jco.2010.28.6674 | PMID 20713849 Get It

Purpose Vitamin D insufficiency is common in the United States, with low levels linked in some studies to higher cancer incidence, including non-Hodgkin's lymphoma (NHL). Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL. Patients and Methods We tested the hypothesis that circulating 25-hydroxyvitamin D [25(OH)D] levels are predictive of event-free survival (EFS) and overall survival (OS) in a prospective cohort of 983 newly diagnosed patients with NHL. 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels were measured by liquid chromatography-tandem mass spectrometry. Results Mean age at diagnosis was 62 years (range, 19 to 94 years); 44% of patients had insufficient 25(OH)D levels (< 25 ng/mL) within 120 days of diagnosis. Median follow-up was 34.8 months; 404 events and 193 deaths (168 from lymphoma) occurred. After adjusting for known prognostic factors and treatment, 25(OH)D insufficient patients with diffuse large B-cell lymphoma (DLBCL) had inferior EFS (hazard ratio [HR], 1.41; 95% CI, 0.98 to 2.04) and OS (HR, 1.99; 95% CI, 1.27 to 3.13); 25(OH)D insufficient patients with T-cell lymphoma also had inferior EFS (HR, 1.94; 95% CI, 1.04 to 3.61) and OS (HR, 2.38; 95% CI, 1.04 to 5.41). There were no associations with EFS for the other NHL subtypes. Among patients with DLBCL and T-cell lymphoma, higher 1,25(OH)2D levels were associated with better EFS and OS, suggesting that any putative tumor 1-α-hydroxylase activity did not explain the 25(OH)D associations. Conclusion 25(OH)D insufficiency was associated with inferior EFS and OS in DLBCL and T-cell lymphoma. Whether normalizing vitamin D levels in these patients improves outcomes will require testing in future trials.
Coordination of Substrate Binding and ATP Hydrolysis in Vps4-Mediated ESCRT-III Disassembly
Davies, Brian A., Azmi, Ishara F. , Payne, Johanna A., Shestakova, Anna , Horazdovsky, Bruce , Babst, Markus , Katzmann, David J.

Molecular Biology of the Cell | August 12, 2010 | Volume: 21 | Issue: 19 | Pages: 3396-3408

10.1091/mbc.e10-06-0512 | PMID 20702581 Get It

ESCRT-III undergoes dynamic assembly and disassembly to facilitate membrane exvagination processes including multivesicular body (MVB) formation, enveloped virus budding, and membrane abscission during cytokinesis. The AAA-ATPase Vps4 is required for ESCRT-III disassembly, however the coordination of Vps4 ATP hydrolysis with ESCRT-III binding and disassembly is not understood. Vps4 ATP hydrolysis has been proposed to execute ESCRT-III disassembly as either a stable oligomer or an unstable oligomer whose dissociation drives ESCRT-III disassembly. An in vitro ESCRT-III disassembly assay was developed to analyze Vps4 function during this process. The studies presented here support a model in which Vps4 acts as a stable oligomer during ATP hydrolysis and ESCRT-III disassembly. Moreover, Vps4 oligomer binding to ESCRT-III induces coordination of ATP hydrolysis at the level of individual Vps4 subunits. These results suggest that Vps4 functions as a stable oligomer that acts upon individual ESCRT-III subunits to facilitate ESCRT-III disassembly.
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
Turner, Jennifer , Morton, Lindsay M. , Linet, Martha S. , Vajdic, Claire M. , Monnereau, Alain, Marcos‐Gragera, Rafael , Costantini, Adele Seniori , Cerhan, James R. , Weisenburger, Dennis D. , Monnereau, Alain , Clarke, Christina A. , Kadin, Marshall E. , Maynadié, Marc , Chiu, Brian C.‐H. , Cerhan, James R , Turner, Jennifer , Vajdic, Claire M , Morton, Lindsay M , Marcos-Gragera, Rafael

Blood | August 11, 2010 | Volume: 116 | Issue: 20 | Pages: e90-e98

10.1182/blood-2010-06-289561 | PMID 20699439 Get It

Abstract After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and “in situ” lesions, disorders with limited capacity for clinical progression, lesions without current International Classification of Diseases for Oncology, 3rd Edition codes, and immunodeficiency-associated lymphoproliferative disorders. WHO subtypes are defined in hierarchical groupings, with newly defined groups for small B-cell lymphomas with plasmacytic differentiation and for primary cutaneous T-cell lymphomas. We suggest approaches for applying the hierarchical classification in various epidemiologic settings, including strategies for dealing with multiple coexisting lymphoma subtypes in one patient, and cases with incomplete pathologic information. The pathology materials useful for state-of-the-art epidemiology studies are also discussed. We encourage epidemiologists to adopt the updated InterLymph hierarchical classification, which incorporates the most recent WHO entities while demonstrating their relationship to older classifications.
Increased Reactive Oxygen Species Production and Lower Abundance of Complex I Subunits and Carnitine Palmitoyltransferase 1B Protein Despite Normal Mitochondrial Respiration in Insulin-Resistant Human Skeletal Muscle
Lefort, Natalie , Glancy, Brian , Willis, Wayne T. , Bailowitz, Zachary, Filippis, Elena A. De, Brophy, Colleen M., Højlund, Kurt , Yi, Zhengping , Mandarino, Lawrence J. , Bowen, Benjamin P. , Meyer, Christian , Glancy, Brian

Diabetes | August 4, 2010 | Volume: 59 | Issue: 10 | Pages: 2444-2452

10.2337/db10-0174 | PMID 20682693 Get It

OBJECTIVE The contribution of mitochondrial dysfunction to skeletal muscle insulin resistance remains elusive. Comparative proteomics are being applied to generate new hypotheses in human biology and were applied here to isolated mitochondria to identify novel changes in mitochondrial protein abundance present in insulin-resistant muscle. RESEARCH DESIGN AND METHODS Mitochondria were isolated from vastus lateralis muscle from lean and insulin-sensitive individuals and from obese and insulin-resistant individuals who were otherwise healthy. Respiration and reactive oxygen species (ROS) production rates were measured in vitro. Relative abundances of proteins detected by mass spectrometry were determined using a normalized spectral abundance factor method. RESULTS NADH- and FADH2-linked maximal respiration rates were similar between lean and obese individuals. Rates of pyruvate and palmitoyl-dl-carnitine (both including malate) ROS production were significantly higher in obesity. Mitochondria from obese individuals maintained higher (more negative) extramitochondrial ATP free energy at low metabolic flux, suggesting that stronger mitochondrial thermodynamic driving forces may underlie the higher ROS production. Tandem mass spectrometry identified protein abundance differences per mitochondrial mass in insulin resistance, including lower abundance of complex I subunits and enzymes involved in the oxidation of branched-chain amino acids (BCAA) and fatty acids (e.g., carnitine palmitoyltransferase 1B). CONCLUSIONS We provide data suggesting normal oxidative capacity of mitochondria in insulin-resistant skeletal muscle in parallel with high rates of ROS production. Furthermore, we show specific abundance differences in proteins involved in fat and BCAA oxidation that might contribute to the accumulation of lipid and BCAA frequently associated with the pathogenesis of insulin resistance.
Dyssynchrony Indices To Predict Response to Cardiac Resynchronization Therapy
Miyazaki, Chinami , Redfield, Margaret M. , Powell, Brian D. , Lin, Grace, Herges, Regina M., Hodge, David O. , Olson, Lyle J. , Hayes, David L. , Espinosa, Raúl E. , Rea, Robert F., Nelson, Susan M., Miller, Fletcher A., Oh, Jae K. , Bruce, Charles J.

Circulation: Heart Failure | July 21, 2010 | Volume: 3 | Issue: 5 | Pages: 565-573

10.1161/circheartfailure.108.848085 | PMID 20647479 Get It

Background— Whether mechanical dyssynchrony indices predict reverse remodeling (RR) or clinical response to cardiac resynchronization therapy (CRT) remains controversial. This prospective study evaluated whether echocardiographic dyssynchrony indices predict RR or clinical response after CRT. Methods and Results— Of 184 patients with heart failure with anticipated CRT who were prospectively enrolled, 131 with wide QRS and left ventricular ejection fraction <35% had 6-month follow-up after CRT implantation. Fourteen dyssynchrony indices (feasibility) by M-mode (94%), tissue velocity (96%), tissue Doppler strain (92%), 2D speckle strain (65% to 86%), 3D echocardiography (79%), and timing intervals (98%) were evaluated. RR (end-systolic volume reduction ≥15%) occurred in 55% and more frequently in patients without (71%) than in patients with (42%) ischemic cardiomyopathy ( P =0.002). Overall, only M-mode, tissue Doppler strain, and total isovolumic time had a receiver operating characteristic area under the curve (AUC) greater than the line of no information, but none of these were strongly predictive of RR (AUC, 0.63 to 0.71). In nonischemic cardiomyopathy, no dyssynchrony index predicted RR. In ischemic cardiomyopathy, M-mode (AUC, 0.67), tissue Doppler strain (AUC, 0.79), and isovolumic time (AUC, 0.76) -derived indices predicted RR ( P <0.05 for all), although the incremental value was modest. No indices predicted clinical response assessed by Minnesota Living with Heart Failure Questionnaire, 6-minute walk distance, and peak oxygen consumption. Conclusions— These findings are consistent with the Predictors of Response to CRT study and do not support use of these dyssynchrony indices to guide use of CRT.
Iodixanol Versus Low-Osmolar Contrast Media for Prevention of Contrast Induced Nephropathy
From, Aaron M., Badarin, Firas Al , McDonald, Furman S., Bartholmai, Brian J. , Cha, Stephen S., Rihal, Charanjit S. , Cha, Stephen S., Rihal, Charanjit S. , Bartholmai, Brian J

Circulation: Cardiovascular Interventions | July 21, 2010 | Volume: 3 | Issue: 4 | Pages: 351-358

10.1161/circinterventions.109.917070 | PMID 20647563 Get It

Background— Contrast-induced nephropathy (CIN) is associated with significant morbidity and mortality. The objective of our meta-analysis was to assess the efficacy of iodixanol compared with low-osmolar contrast media (LOCM) for prevention of CIN. Methods and Results— We searched MEDLINE, the Cochrane Central Register of Controlled Trials, and internet sources of cardiology trial results for individual and relevant reviews of randomized, controlled trials, for the terms contrast media, contrast nephropathy, renal failure, iodixanol, Visipaque, and low-osmolar contrast media. All studies reported an incidence rate of CIN for each study group; there was no restriction on the definition of CIN. There were no restrictions on journal type or patient population. Overall, 36 trials were identified for analysis of aggregated summary data on 7166 patients; 3672 patients received iodixanol and 3494 patients received LOCM. Overall, iodixanol showed no statistically significant reduction in CIN incidence below that observed with heterogeneous comparator agents ( P =0.11). Analysis of patient subgroups revealed that there was a significant benefit of iodixanol when compared with iohexol alone (odds ratio, 0.25; 95% confidence interval, 0.11 to 0.55; P <0.001) but not when compared with LOCM other than iohexol or with other ionic dimers or among patients receiving intra-arterial contrast injections or among patients undergoing coronary angiography with or without percutaneous intervention. Conclusions— Analysis of aggregated summary data from multiple randomized, controlled trials of iodixanol against diverse LOCMs for heterogeneous procedures and definitions of CIN show an iodixanol-associated reduction that is suggestive but statistically nonsignificant.
Operating Room Pooling and Parallel Surgery Processing Under Uncertainty
Batun, Sakine , Huschka, Todd R., Schaefer, Andrew J. , Denton, Brian T.

INFORMS Journal on Computing | July 3, 2010 | Volume: 23 | Issue: 2 | Pages: 220-237

10.1287/ijoc.1100.0396 Get It

Operating room (OR) scheduling is an important operational problem for most hospitals. In this study, we present a novel two-stage stochastic mixed-integer programming model to minimize total expected operating cost given that scheduling decisions are made before the resolution of uncertainty in surgery durations. We use this model to quantify the benefit of pooling ORs as a shared resource and to illustrate the impact of parallel surgery processing on surgery schedules. Decisions in our model include the number of ORs to open each day, the allocation of surgeries to ORs, the sequence of surgeries within each OR, and the start time for each surgeon. Realistic-sized instances of our model are difficult or impossible to solve with standard stochastic programming techniques. Therefore, we exploit several structural properties of the model to achieve computational advantages. Furthermore, we describe a novel set of widely applicable valid inequalities that make it possible to solve practical instances. Based on our results for different resource usage schemes, we conclude that the impact of parallel surgery processing and the benefit of OR pooling are significant. The latter may lead to total cost reductions between 21% and 59% on average.
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica
Matiello, Marcelo , Schaefer-Klein, Janet, Brum, Doralina Guimarães , Atkinson, Elizabeth J. , Kantarci, Orhun H. , Weinshenker, Brian G. , collaborators, the NMO genetics, Weinshenker, Brian G

Multiple Sclerosis Journal | June 30, 2010 | Volume: 16 | Issue: 8 | Pages: 981-984

10.1177/1352458510374340 | PMID 20591987 Get It

Background: Association of the HLA-DRB1*1501 allele with multiple sclerosis is well established, but its association with neuromyelitis optica has only been evaluated in small populations. Methods: We performed a case-control genetic association study to evaluate the association of HLA-DRB1*1501 with neuromyelitis optica. The single nucleotide polymorphism rs3135388, which tags HLA-DRB1*1501, was genotyped in 164 patients with neuromyelitis optica, 220 patients with multiple sclerosis and 959 controls matched for age, gender and ethnicity. Genotyping for rs3135388 was performed by Taqman-based 5' nuclease assay. Results: Rs3135388*A was positively associated with multiple sclerosis (OR = 3.93; 95% CI = 2.58—5.97, p = 1.18 × 10 -09 ) but negatively associated with NMO (OR = 0.57; 95% CI = 0.36—0.91, p = 0.01). Conclusions: Multiple sclerosis and neuromyelitis optica differ in their associations with DRB1*1501.